204 related articles for article (PubMed ID: 21282717)
21. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Haematologica; 2009 Dec; 94(12):1762-6. PubMed ID: 19797731
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
[No Abstract] [Full Text] [Related]
23. [The 5q- syndrome].
Adès L; Fenaux P
Rev Prat; 2010 Dec; 60(10):1420-2. PubMed ID: 21425544
[No Abstract] [Full Text] [Related]
24. Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?
Abdallah M; Reichard K; Gangat N; Tefferi A
Blood Cancer J; 2024 Mar; 14(1):49. PubMed ID: 38499527
[No Abstract] [Full Text] [Related]
25. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
27. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
[No Abstract] [Full Text] [Related]
28. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Voutsadakis IA; Cairoli A
Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
30. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
Cerchione C; Catalano L; Cerciello G; Avilia S; Picardi M; Risitano AM; Pisano I; Alfinito F; Pane F
Ann Hematol; 2015 Mar; 94(3):531-4. PubMed ID: 25135452
[No Abstract] [Full Text] [Related]
31. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
[TBL] [Abstract][Full Text] [Related]
32. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
33. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA
Ann Hematol; 2008 May; 87(5):345-52. PubMed ID: 18265982
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide for treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
Jädersten M
Haematologica; 2010 Mar; 95(3):348-51. PubMed ID: 20207839
[No Abstract] [Full Text] [Related]
38. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
[No Abstract] [Full Text] [Related]
39. Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A; Al-Kali A; Foran JM; Elliott MA; Begna K; Badar T; Khera N; Fleti F; Abdelmagid M; Reichard KK; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2022 Oct; 97(10):E377-E379. PubMed ID: 35959963
[No Abstract] [Full Text] [Related]
40. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
